{'fraction_non_alphanumeric': 0.029173419773095625, 'fraction_numerical': 0.0016207455429497568, 'mean_word_length': 5.4375, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Immunosuppressive Potential and Side Effects of Everolimus

We acknowledge the thoughtful comments by Pascual and Arns (1) highlighting the importance of this topic. We agree that small differences in trial design and demographics are limitations and our single-center analysis may not be representative for others. However, we could not find any evidence that those minor differences influence the development of donor-specific antibodies (DSA) and all randomized patients were analyzed according to the intention-to-treat principle. Finally, multivariate analyses tried to adjust for those imbalances (e.g. gender).